Inhibikase Therapeutics annual return on equity
2021
2022
2023
2024
2025
Inhibikase Therapeutics Return on Equity (ROE) Growth & History (IKT)
Inhibikase Therapeutics's return on equity was −36.05% for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −36.05% | +15.96 pp |
| 2024 | 2024-12-31 | −52.00% | +66.88 pp |
| 2023 | 2023-12-31 | −118.88% | −58.14 pp |
| 2022 | 2022-12-31 | −60.74% | +0.62 pp |
| 2021 | 2021-12-31 | −61.35% | — |
Inhibikase Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −12.21% | −0.25 pp |
| Q1 2026 | 2026-03-31 | −9.62% | +5.53 pp |
| Q4 2025 | 2025-12-31 | −10.36% | +15.36 pp |
| Q3 2025 | 2025-09-30 | −15.60% | +237.49 pp |
| Q2 2025 | 2025-06-30 | −11.96% | +71.58 pp |
| Q1 2025 | 2025-03-31 | −15.15% | +37.23 pp |
| Q4 2024 | 2024-12-31 | −25.72% | +6.42 pp |
| Q3 2024 | 2024-09-30 | −253.09% | −226.44 pp |
| Q2 2024 | 2024-06-30 | −83.54% | −57.72 pp |
| Q1 2024 | 2024-03-31 | −52.38% | −33.04 pp |
| Q4 2023 | 2023-12-31 | −32.14% | −13.61 pp |
| Q3 2023 | 2023-09-30 | −26.65% | −10.20 pp |
| Q2 2023 | 2023-06-30 | −25.82% | −11.21 pp |
| Q1 2023 | 2023-03-31 | −19.33% | −6.52 pp |
| Q4 2022 | 2022-12-31 | −18.54% | −6.18 pp |
| Q3 2022 | 2022-09-30 | −16.45% | −6.54 pp |
| Q2 2022 | 2022-06-30 | −14.61% | −5.04 pp |
| Q1 2022 | 2022-03-31 | −12.81% | +16.78 pp |
| Q4 2021 | 2021-12-31 | −12.36% | — |
| Q3 2021 | 2021-09-30 | −9.91% | — |
| Q2 2021 | 2021-06-30 | −9.57% | — |
| Q1 2021 | 2021-03-31 | −29.60% | — |
Inhibikase Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Inhibikase Therapeutics's return on equity increased from −61.35% to −36.05%, a change of +25.31 percentage points. The latest reported quarter, Q2 2026, shows −12.21%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗